Resolution Therapeutics will present new preclinical data on its engineered regenerative macrophage therapy, RTX001, in an oral presentation at the ASGCT Annual Meeting in Boston.
According to the company, the data demonstrate RTX001’s pharmacology and pharmacokinetic profile, safety and tolerability in mouse models, and efficacy at reducing liver enzymes, inflammation, and fibrosis. The company claims these findings support RTX001’s anti-inflammatory and anti-fibrotic potential ahead of interim results from its Phase I/II EMERALD trial, expected in the second half of 2026.
The presentation, titled Preclinical development of an engineered regenerative macrophage therapy for end-stage liver disease, was delivered by Lara Campana on 12 May 2026, during the Novel T-cell and myeloid strategies session. Resolution, a University of Edinburgh spinout with operations in Edinburgh and London, is advancing RTX001 as its lead program and is exploring broader fibrotic and inflammatory indications including graft-versus-host disease and lung fibrosis.
